Zydus Wellness Limited shareholders approved a dividend of ₹1.20 per equity share and re-elected Dr. Sharvil P. Patel as a Non-Executive Director during its 32nd Annual General Meeting (AGM) held on August 4, 2026. The meeting, conducted via Video Conference and Other Audio Visual Means (OAVM), also saw the appointment of Apurva S. Diwanji as an Independent Director for a five-year term. While financial resolutions passed with near-unanimous support, the re-appointment of Dr. Patel faced significant opposition from institutional investors, highlighting divergent views on board composition.

The voting process was scrutinized by Hitesh Buch & Associates under Section 108 of the Companies Act, 2013 and Rule 20(4)(xii) of the Companies (Management and Administration) Rules, 2014. Voting rights were determined based on the register of members as of July 28, 2026, which listed 90,662 shareholders. Remote e-voting was facilitated by Central Depository Services (India) Limited from July 31 to August 3, 2026. Of the 90,662 shareholders, 61 attended the meeting via video conference, comprising 51 promoters and 10 public shareholders.

AGM Voting Results

Shareholders overwhelmingly supported the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The dividend declaration received near-unanimous support. However, the re-appointment of Dr. Sharvil P. Patel saw notable opposition, particularly from institutional investors who voted against the resolution at a rate of 10.88%. The appointment of Apurva S. Diwanji also faced resistance from institutions, with 53.20% voting against.

Dr. Sharvil P. Patel, who served as Chairman of the AGM, declared all resolutions passed pursuant to Section 108 and 109 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were submitted to BSE Limited and National Stock Exchange of India Limited on August 4, 2026.

What the Numbers Show

The voting data reveals a distinct divergence in shareholder sentiment regarding board appointments versus routine financial matters. While resolutions concerning financial statements and dividends achieved near-perfect consensus (above 99.99%), the re-appointment of Dr. Sharvil P. Patel faced notable opposition. Specifically, while promoter groups voted unanimously in favor, Public – Institutions voted against the resolution by 10.88%. Similarly, the appointment of Apurva S. Diwanji saw 53.20% opposition from institutions, despite strong support from promoters and non-institutional public shareholders. This pattern suggests active engagement from institutional investors on governance matters, even as operational and financial approvals remain uncontested.

Zydus Wellness reported a consolidated net profit of ₹1,189 million for the quarter ended June 30, 2026 (Q1FY26), down from ₹1,279 million in the same period last year. Despite this decline in bottom-line profitability, the company’s top line expanded significantly, with revenue from operations rising 67% year-on-year to ₹14,370 million from ₹8,609 million. The divergence between revenue growth and profit contraction was driven by increased operational costs, particularly in advertisement and promotion, which expanded the cost base faster than earnings could absorb it following recent strategic acquisitions.

Q1FY26 Financial Performance

The Board of Directors approved the unaudited financial results on August 4, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and limited reviewed by Mukesh M. Shah & Co., the statutory auditors. The trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015 remained closed until August 6, 2026, reopening for directors and designated persons on August 7, 2026.

Revenue growth was primarily fueled by the inclusion of Comfort Click Limited (CCL), acquired by subsidiary Alidac UK Limited in August 2025, and the consolidation of Naturell (India) Private Limited (NIPL) business effective September 20, 2025. However, total expenses rose sharply to ₹12,787 million from ₹7,186 million. Advertisement and promotion expenses more than doubled to ₹2,612 million from ₹1,325 million, while other expenses jumped to ₹3,435 million from ₹1,171 million. Consequently, while absolute EBITDA expanded to ₹2,420 million from ₹1,560 million, the EBITDA margin contracted to 16.82% from 18.10%.

Key Operational Developments

The company operates in a single segment: "Consumer Products." The acquisition of CCL by Alidac UK Limited for GBP 239 million plus a profit-ticker payment of GBP 2.64 million has significantly expanded the group's international footprint. The financial results include CCL's operations from August 29, 2025, based on provisional purchase price allocation figures. Additionally, the voluntary liquidation of NIPL was completed, with its business undertaking distributed to Zydus Wellness on a going concern basis, consolidating its operations from September 20, 2025.

Tax and Exceptional Items

Total tax expense increased to ₹432 million from ₹174 million in Q1FY25. This includes a reversal of Minimum Alternate Tax (MAT) credit entitlement of Nil for Q1FY26, compared to ₹146 million in the prior year period. There were no exceptional items in Q1FY26. In contrast, FY25 saw exceptional expenses related to NIPL liquidation and CCL acquisition totaling ₹408 million, which included costs associated with the new Labour Codes.

Standalone Results

On a standalone basis, Zydus Wellness posted a net profit of ₹55 million for Q1FY26, up from ₹46 million in Q1FY25. Standalone revenue from operations was ₹1,530 million, compared to ₹1,409 million in the previous year. The standalone profit before tax stood at ₹74 million, slightly lower than ₹79 million in Q1FY25. The company had previously approved the split of equity shares from a face value of ₹10 to ₹2 each, which was effected on September 19, 2025.